Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ViroChem Pharma Inc.

Division of Vertex Pharmaceuticals Inc.
www.virochempharma.com

Latest From ViroChem Pharma Inc.

Stockwatch: Humans – the weak link in drug development

The announcement on 4 September that Gilead Sciences, after consultation with the FDA, will be dropping its experimental anti-hepatitis C virus (HCV) compound GS 9190 (tegobuvir) from ongoing clinical trials after two serious adverse events, will cast doubts on this potentially hot target in the treatment of HCV infections (scripintelligence.com, 5 September 2011).

Vertex unveils promising VX-222/Incivek combo data in HCV

Vertex Pharmaceuticals has no plans to rest on its laurels in the treatment of HCV. Hot on the heels of getting FDA approval for Incivek (telaprevir), the oral HCV protease inhibitor developed in collaboration with the Janssen Pharmaceutical company Tibotec Virco (scripintelligence.com, 23 May 2011), the company has unveiled interim Phase II data highlighting the potential of VX-222, its lead hepatitis C virus polymerase inhibitor, as part of a combination approach to treating genotype-1 hepatitis C.

Germany

2009's Private Biotech Acquisitions Are a Tale of Two Step-Ups

Not every acquisition of a venture-backed biotech in 2009 was a structured deal that included earn-outs based on clinical or regulatory milestones. But it sure was close. Thirteen private biotechnology companies were acquired in 2009 and of those deals only a few did not include contingent value rights (CVRs).
BioPharmaceutical Business Strategies

In HCV, Protease Race Heats Up with Combo Therapy Looming

Two Phase III hepatitis C protease inhibitors from Vertex and Schering are set to reshape treatment for a difficult disease and potentially capture a significant chunk of a large and growing market. But other new therapies and combination regimens aren't far behind.
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Vertex Pharmaceuticals Inc.
  • Senior Management
  • Gervais Dionne, PhD, CEO & CSO
    François Legault , Pres. & COO
    Domenic De Luca, Dir., Fin. & Admin.
  • Contact Info
  • ViroChem Pharma Inc.
    Phone: (450) 978-7700
    275 Armand-Frappier Blvd.
    Laval, H7V 4A7
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register